TLR4 and Sepsis: Despite its beneficial effects on survival in animal models of sepsis32,61,62, clinical trials of TAK-24238 and other TLR4 antagonists63 have failed to observe a significant improvement of the 28-day mortality rate of patients with sepsis and septic shock.